NextCure, Inc. Profile Avatar - Palmy Investing

NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is i…

Biotechnology
US, Beltsville [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

NextCure, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of NXTC's Analysis
CIK: 1661059 CUSIP: 65343E108 ISIN: US65343E1082 LEI: - UEI: -
Secondary Listings
NXTC has no secondary listings inside our databases.